

# INJECTABLE TREATMENTS FOR **OSTEOPOROSIS**



# WHAT IS OSTEOPOROSIS?


Bone is a living tissue that is broken down and renewed all the time. The renewal process slows with age, so it is normal for your bones to become weaker and less dense (bone loss) as you grow older. But some people lose bone faster than others, which makes bones weak and thin. This is known as osteoporosis, which is usually a long-term (chronic) condition that happens slowly over several years.

Most patients with osteoporosis experience little to no symptoms. They usually only find out that they have the condition after they break a bone (fracture). If the bones in the spine break, the body will be unable to support itself properly, leading to a bent-forward posture that may affect balance and increase the risk of falling.


**DID YOU KNOW?** 

Women have a higher risk of osteoporosis, but the condition can affect anyone, including men.1

Learn more facts about osteoporosis here.2



# Fractures due to osteoporosis commonly happen in the:



# **HOW TO PREVENT OSTEOPOROSIS AND FRACTURES?**

Your risk of osteoporosis increases with certain factors such as being underweight, drinking or smoking heavily, having family members with the condition, not taking enough calcium, or not exercising regularly. If you are at risk of osteoporosis, you can reduce your fracture risk by strengthening your bones and taking precautions to prevent falls:3,4



# **HOW IS OSTEOPOROSIS TREATED?**

Some patients may be suitable for treatment with drugs to strengthen their bones. These treatments are available as oral tablets, or given as injections into the fat under the skin, or slow drips into the vein. Your doctor will assess your age, sex, risk of fractures, injury history, and preferences to advise which treatment is suitable for you.





# Injectable drugs such as

- denosumab
- teriparatide
- romosozumab
- zoledronic acid

### Did you know?

Denosumab, romosozumab and teriparatide are medicines that contain active ingredients made by living cells. These are called biological medicines or biologics. Biosimilars are also

biologics. Click here to

learn more about them.5



# WHAT DOES THE EVIDENCE FROM CLINICAL STUDIES SAY ABOUT INJECTABLE DRUGS FOR TREATING OSTEOPOROSIS?

ACE reviewed the available clinical evidence and received expert advice from doctors and patients about the use of injectable drugs to treat osteoporosis. ACE also negotiated the prices of these drugs with the companies. 6,7,8

Denosumab, romosozumab, teriparatide, and zoledronic acid are effective treatment options for increasing the amount of minerals in bones (bone mineral density) or reducing the risk of fractures in women.

Denosumab, teriparatide, and zoledronic acid are effective treatment options for men with osteoporosis.





# SUBSIDISED INJECTABLE DRUGS FOR OSTEOPOROSIS

# Subsidised (brand name)9

- Denosumab (Prolia)
- Zoledronic acid (all brands)
- Teriparatide biosimilar (Sondelbay)\*
- \*For patients with severe osteoporosis who have had two or more fractures in their spine, or other bones due to osteoporosis.

# Not Subsidised<sup>^</sup>

- 🔀 Romosozumab
- 🔀 Teriparatide (brands other than Sondelbay, such as Forteo)

^Not subsidised because their benefits do not justify their costs at the prices offered by the companies.<sup>7,8</sup>

Treatment costs are subsidised by 40% to 75% for eligible patients



# **KEY MESSAGES**

Injectable drugs such as denosumab, zoledronic acid, and teriparatide biosimilar (Sondelbay) are subsidised for certain patients with osteoporosis, making them more affordable. The treatment that you need will depend on different factors such as your age, sex, risk of fractures, injury history, and preferences. Discuss with your doctor which treatment is suitable for you, and your concerns. You can also speak to a medical social worker if you need financial assistance for any treatments.

### Sources

- ACE Clinical Guideline on Osteoporosis: diagnosis and management, 15 August 2025
- 2. ACE Patient Education Aid on Osteoporosis: know the facts, 15 August 2025 www.healthhub.sg/well-being-and-lifestyle/active-ageing/keeping-bones-strong
- www.healthhub.sg/well-being-and-lifestyle/active-ageing/tips-on-fall-prevention
- ACE Patient Factsheet on Biosimilars: A Safe, Effective and More Affordable Option for Patients, 2025
- 6. ACE technology guidance for Denosumab for treating osteoporosis and glucocorticoid-associated bone loss, July 2022
- ACE technology guidance for Romosozumab and teriparatide for treating osteoporosis, June 2025
- 8. ACE technology guidance for Teriparatide biosimilar for treating osteoporosis, June 2025
- $9. \ www.moh.gov.sg/managing-expenses/schemes-and-subsidies/list-of-subsidised-drugs$



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. It publishes guidances on diagnosing, treating, and preventing different medical conditions based seek the advice of a qualified healthcare professional about any medical condition. © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore. All rights reserved. Reproduction of this publication in whole or part in any material form is prohibited without the prior written permission of the copyright holder.